Allan Gobbs, Co-Founder and Managing Partner of ATEM Capital. See sector focus and contact routes.
Allan Gobbs, Co-Founder and Managing Partner of ATEM Capital, primarily invests in late-stage biopharma companies with proven human proof of concept, allocating roughly 50% of the fund to this sector while also investing 20% in early-stage biopharma and 30% in digital health. His distinctive thesis favors a conservative strategy targeting assets with established clinical data, and his portfolio includes notable exits such as Atea Pharmaceuticals (40x IPO return), Syndax Pharmaceuticals, and Amolyt Pharma, which was sold to AstraZeneca for over $1 billion. For early-stage health tech startups, Gobbs typically makes initial checks of $500,000 to $750,000, reserving capital to support companies through their growth journey.
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in New York.
Investors like Allan Gobbs · Full investor directory · Investor access · Company funding database